Webinar: Making API candidate selection more productive
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
List view / Grid view
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
Streamline your cancer research using this guide that groups antibodies against critical cancer biomarkers according to biomarker type or tissue type.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Sino Biological’s “FucoFree” eukaryotic expression system provides high-yield and high-throughput afucosylated monoclonal antibody (mAb) production.
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
Compendium of iQue® advanced flow cytometry platform application posters: Antibody discovery and immuno-oncology.